SNGX: Phase 3 Trial of HyBryte in CTCL to Initiate in 2H24
On August 9, 2024, Soligenix, Inc. (SNGX) announced financial results for the second quarter of 2024 and provided a business update. The company...
129 Views
SNGX: Phase 3 Trial of HyBryte in CTCL to Initiate in 2H24
On August 9, 2024, Soligenix, Inc. (SNGX) announced financial results for the second quarter of 2024 and provided a business update. The company...
142 Views
SNGX: Positive Interim Results for HyBryte in Investigator-Initiated Study in CTCL Raising Valuation to 35
On July 9, 2024, Soligenix, Inc. (SNGX) announced positive interim results for HyBryte in an open-label, investigator-initiated study in patients...
185 Views
SNGX: Valuation Change Based on Reverse Split
On June 6, 2024, Soligenix, Inc. (SNGX) enacted a reverse stock split at a ratio of 1 post-split share for every 16 pre-split shares. Our...
140 Views
SNGX: Second Confirmatory Phase 3 Trial of HyBryte in CTCL to Initiate Before End of 2024
On May 10, 2024, Soligenix, Inc. (SNGX) announced financial results for the first quarter of 2024 and provided a business update. The company...
144 Views